WOCKHARDT Latest Share Price (WOCKPHARMA)
TODAY IN ONE LINE
WOCKPHARMA surged 7.1% on above-average volume (2.0x avg), outperforming Nifty's 0.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹33,908.05 Cr., it trades at a P/E of 75.68. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
WOCKHARDT flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 28.4%
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 39.6% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 150.3x
- ●Promoter SellingPromoter holding decreased by 49.09% QoQ
- ●Rising Receivables vs SalesReceivables grew 20.1% outpacing sales growth of 7.6%
Latest WOCKHARDT News
What changed recently?
Recent events, corporate actions, and announcements.
WOCKHARDT valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for WOCKHARDT, framed against the sector median so the premium or discount is obvious at a glance.
WOCKHARDT trades at a P/E of 75.68× and P/B of 6.27×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
WOCKHARDT technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for WOCKHARDT — derived from the latest tape, not yesterday's close.
WOCKHARDT last traded at ₹2,088.7 with an intraday range of ₹1,976.1–₹2,108.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2088.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2404.23 | +315.53 | +15.11% |
| R3 | 2271.83 | +183.13 | +8.77% |
| R2 | 2190.17 | +101.47 | +4.86% |
| R1 | 2139.43 | +50.73 | +2.43% |
| PIVOT | 2057.77 | -30.93 | -1.48% |
| CURRENT | 2088.70 | — | — |
| S1 | 2007.03 | -81.67 | -3.91% |
| S2 | 1925.37 | -163.33 | -7.82% |
| S3 | 1874.63 | -214.07 | -10.25% |
| S4 | 1742.23 | -346.47 | -16.59% |
WOCKPHARMA is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1976.1–₹2017.7
Trading Above opening range, showing Bullishness
WOCKHARDT financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for WOCKHARDT — consolidated or standalone — with margins, YoY growth and key ratios inline.
WOCKHARDT reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹33,908.05 Cr. and reported EPS of ₹6.58.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,012 | 3,373 ▲ 12.0% |
| Sales Growth YoY %Derived | 7.65% | 11.99% |
| Other Income | 62 | 111 ▲ 79.0% |
| Total Income | 3,074 | 3,484 ▲ 13.3% |
| 1,132 | 1,132 ▲ 0.0% | |
| Gross ProfitDerived | 1,880 | 2,241 ▲ 19.2% |
| Gross Margin %Derived | 62.42% | 66.44% |
| 1,487 | 1,589 ▲ 6.9% | |
| EBITDA (Operating Profit)Derived | 393 | 652 ▲ 65.9% |
| OPM %Derived | 13.05% | 19.33% |
| 471 | 355 ▼ 24.6% | |
| Profit Before Tax (PBT) | -16 | 238 ▲ 1587.5% |
| 41 | 39 ▼ 4.9% | |
| Effective Tax %Derived | -256.25% | 16.39% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | -57 | 199 ▲ 449.1% |
| Less: Non-controlling Interests | -10 | -14 ▼ 40.0% |
| Net Profit (Owner's PAT)Derived | -47 | 213 ▲ 553.2% |
| Net Profit Margin %Derived | -1.56% | 6.31% |
| PAT Growth YoY %Derived | 89.85% | 553.19% |
| Earnings Per Share (EPS ₹) | -2.89 | 13.11 ▲ 553.6% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 71 | 419 ▲ 490.1% |
| Total Expenses (incl. D&A & Interest) | 3,090 | 3,246 ▲ 5.0% |
| Material Cost % of RevenueDerived | 20.32% | 19.98% |
| Employee Cost % of RevenueDerived | 21.61% | 21.49% |
| Other Cost % of RevenueDerived | 27.76% | 25.62% |
| Interest Coverage (x)Derived | 0.69x | 2.00x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,937 | 4,158 ▲ 5.6% | 2,844 ▼ 31.6% | 2,708 ▼ 4.8% | 3,230 ▲ 19.3% | 2,651 ▼ 17.9% | 2,798 ▲ 5.5% | 3,012 ▲ 7.6% | 3,373 ▲ 12.0% | |
| Sales Growth YoY %Derived | — | 5.63% | -31.61% | -4.77% | 19.26% | -17.93% | 5.55% | 7.65% | 11.99% | |
| Other Income | 120 | 21 ▼ 82.5% | 39 ▲ 84.6% | 132 ▲ 240.8% | 20 ▼ 84.9% | 122 ▲ 510.0% | 83 ▼ 32.0% | 62 ▼ 25.3% | 111 ▲ 79.0% | |
| Total Income | 4,057 | 4,179 ▲ 3.0% | 2,883 ▼ 31.0% | 2,841 ▼ 1.5% | 3,250 ▲ 14.4% | 2,773 ▼ 14.7% | 2,881 ▲ 3.9% | 3,074 ▲ 6.7% | 3,484 ▲ 13.3% | |
1,798 | 1,815 ▲ 1.0% | 1,203 ▼ 33.7% | 1,135 ▼ 5.6% | 1,267 ▲ 11.6% | 1,111 ▼ 12.3% | 1,165 ▲ 4.9% | 1,132 ▼ 2.8% | 1,132 ▲ 0.0% | ||
| Gross ProfitDerived | 2,139 | 2,344 ▲ 9.6% | 1,641 ▼ 30.0% | 1,573 ▼ 4.1% | 1,963 ▲ 24.8% | 1,540 ▼ 21.5% | 1,633 ▲ 6.0% | 1,880 ▲ 15.1% | 2,241 ▲ 19.2% | |
| Gross Margin %Derived | 54.34% | 56.36% | 57.68% | 58.07% | 60.77% | 58.09% | 58.36% | 62.42% | 66.44% | |
2,138 | 2,234 ▲ 4.5% | 1,522 ▼ 31.9% | 1,636 ▲ 7.5% | 1,665 ▲ 1.8% | 1,439 ▼ 13.6% | 1,594 ▲ 10.8% | 1,487 ▼ 6.7% | 1,589 ▲ 6.9% | ||
| EBITDA (Operating Profit)Derived | 2 | 110 ▲ 5888.5% | 119 ▲ 8.6% | -63 ▼ 153.0% | 298 ▲ 572.8% | 101 ▼ 66.1% | 39 ▼ 61.4% | 393 ▲ 907.7% | 652 ▲ 65.9% | |
| OPM %Derived | 0.05% | 2.64% | 4.19% | -2.33% | 9.23% | 3.81% | 1.39% | 13.05% | 19.33% | |
47 | 431 ▲ 820.2% | 500 ▲ 16.0% | 353 ▼ 29.5% | 363 ▲ 2.9% | 259 ▼ 28.7% | 514 ▲ 98.5% | 471 ▼ 8.4% | 355 ▼ 24.6% | ||
| Profit Before Tax (PBT) | -641 | -300 ▲ 53.2% | -342 ▼ 13.9% | -568 ▼ 66.2% | -411 ▲ 27.7% | -624 ▼ 51.8% | -420 ▲ 32.7% | -16 ▲ 96.2% | 238 ▲ 1587.5% | |
26 | -84 ▼ 425.5% | -204 ▼ 144.0% | -272 ▼ 33.1% | -132 ▲ 51.4% | -3 ▲ 97.7% | 52 ▲ 1833.3% | 41 ▼ 21.2% | 39 ▼ 4.9% | ||
| Effective Tax %Derived | -4.01% | 27.86% | 59.67% | 47.79% | 32.12% | 0.48% | -12.38% | -256.25% | 16.39% | |
| Profit/Loss from Discontinued Ops | — | — | 95 | 985 ▲ 942.0% | — ▼ 100.0% | — | — | — | — | |
| Total Profit for Period | -667 | -217 ▲ 67.5% | -43 ▲ 80.0% | 689 ▲ 1687.0% | -279 ▼ 140.5% | -621 ▼ 122.6% | -472 ▲ 24.0% | -57 ▲ 87.9% | 199 ▲ 449.1% | |
| Less: Non-controlling Interests | -59 | -22 ▲ 62.2% | 26 ▲ 216.7% | 3 ▼ 90.2% | -35 ▼ 1478.0% | -62 ▼ 77.1% | -9 ▲ 85.5% | -10 ▼ 11.1% | -14 ▼ 40.0% | |
| Net Profit (Owner's PAT)Derived | -608 | -195 ▲ 68.0% | -69 ▲ 64.4% | 686 ▲ 1091.1% | -244 ▼ 135.6% | -559 ▼ 129.1% | -463 ▲ 17.2% | -47 ▲ 89.8% | 213 ▲ 553.2% | |
| Net Profit Margin %Derived | -15.45% | -4.68% | -2.43% | 25.33% | -7.55% | -21.09% | -16.55% | -1.56% | 6.31% | |
| PAT Growth YoY %Derived | — | 68.02% | 64.42% | 1,091.13% | -135.57% | -129.10% | 17.17% | 89.85% | 553.19% | |
| Earnings Per Share (EPS ₹) | -42.30 | -13.52 ▲ 68.0% | -4.81 ▲ 64.4% | 47.64 ▲ 1090.4% | -16.94 ▼ 135.6% | -38.80 ▼ 129.0% | -30.18 ▲ 22.2% | -2.89 ▲ 90.4% | 13.11 ▲ 553.6% | |
| Diluted Shares Outstanding (Cr) | 14 | 14 ▲ 0.1% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 0.0% | 14 ▲ 0.0% | 15 ▲ 6.5% | 16 ▲ 5.9% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 139 | 9 ▼ 93.5% | 101 ▲ 1020.8% | -4 ▼ 103.9% | -27 ▼ 578.4% | 78 ▲ 388.9% | 6 ▼ 92.3% | 71 ▲ 1083.3% | 419 ▲ 490.1% | |
| Total Expenses (incl. D&A & Interest) | 4,698 | 4,480 ▼ 4.7% | 3,225 ▼ 28.0% | 3,409 ▲ 5.7% | 3,661 ▲ 7.4% | 3,397 ▼ 7.2% | 3,301 ▼ 2.8% | 3,090 ▼ 6.4% | 3,246 ▲ 5.0% | |
| Material Cost % of RevenueDerived | 22.04% | 20.54% | 21.86% | 25.20% | 18.95% | 19.54% | 22.16% | 20.32% | 19.98% | |
| Employee Cost % of RevenueDerived | 23.80% | 22.53% | 26.14% | 28.17% | 23.19% | 24.03% | 22.48% | 21.61% | 21.49% | |
| Other Cost % of RevenueDerived | 30.49% | 31.20% | 27.36% | 32.23% | 28.36% | 30.25% | 34.49% | 27.76% | 25.62% | |
| Interest Coverage (x)Derived | -0.58x | -0.21x | -0.38x | -1.24x | 0.17x | -0.50x | -0.60x | 0.69x | 2.00x |
WOCKHARDT segment analysis : revenue and profit mix.
Disclosed business segments at WOCKHARDT with their share of revenue and profit, switchable between consolidated and standalone reporting.
WOCKHARDT discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for WOCKHARDT.
Our AI distills the core fundamental drivers supporting WOCKHARDT, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
WOCKHARDT's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 49.1% demonstrates strong insider confidence and governance commitment.
Quarterly sales grew 29.90% YoY, signaling recent revenue acceleration momentum.
Quarterly profit surged 688% YoY, indicating significant loss reduction trajectory.
TTM revenue growth 26% reflects strong short-term commercial traction.
Robust R&D pipeline with multiple phase-3 trials in infectious disease therapeutics.
Key Risks.
TTM net margin 3.30% far below peer median, indicating severe pricing pressure.
Operating cash flow per share negative at -₹23.82, liquidity under pressure.
Zero dividend yield offers no direct shareholder returns or capital distribution.
P/E 150.34x and EV/EBITDA 56.90x severely overvalued versus sector peers.
ROE 6.11% and ROCE 7.55% lag peer medians by 60%, capital efficiency critically weak.
Flip Conditions.
Valuation risk. a P/E above 98 (~2.4× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.07. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
WOCKHARDT peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — WOCKHARDT is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
WOCKHARDT chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for WOCKHARDT — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
WOCKHARDT delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for WOCKHARDT over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in WOCKHARDT stood at 31.9% of traded volume, against a 20-day average of 42.9%.
WOCKHARDT announcements: results, concalls, ratings, M&A.
Filings WOCKHARDT sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
WOCKHARDT files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 99 documents below.
Action(s) taken or orders passed
In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and…
Copy of Newspaper Publication
Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we…
Shareholders meeting
Disclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B)…
Monitoring Agency Report
Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI…
Press Release
Wockhardt Limited has informed the Exchange regarding a press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
WOCKHARDT dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue WOCKHARDT has declared, sequenced by announce and record date.
WOCKHARDT corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
WOCKHARDT insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in WOCKHARDT as reported to SEBI — buying and selling signals from the people who know the business best.
WOCKHARDT insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Muayyad Khorakiwala | Insider | 27 Dec 2024 | buy | +1.8 K | — | — |
About WOCKHARDT: business, sector, key facts.
What WOCKHARDT does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
WOCKHARDT operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: WOCKPHARMA, BSE: 532300.
Wockhardt Limited is a multinational pharmaceutical and biotechnology company with a global presence, operating in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and other international markets. Their core business encompasses the manufacturing and trading of a wide range of pharmaceutical, medicinal, botanical, and chemical products.
A significant portion of Wockhardt's business focuses on the research and development of innovative products, particularly in the area of infectious diseases. They have several products in various stages of clinical trials, including WCK5222 (phase 3, for sepsis and pneumonia), WCK 4282 (phase 3, for ESBL infections), WCK 6777 (phase 1, for gram-negative infections), and WCK 4873 (phase 3, for community-acquired bacterial pneumonia). This commitment to research and development underscores their strategic focus on advanced therapeutics.
Beyond infectious disease treatments, Wockhardt also manufactures and commercializes a diverse portfolio of products including rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters, and novel products along with their associated delivery devices. This demonstrates a commitment to addressing a broad range of healthcare needs, extending beyond infectious diseases into metabolic disorders.
Wockhardt's product portfolio further includes established commercial products such as Biovac-B (hepatitis B vaccine), WEPOX (recombinant human erythropoietin), WOSULIN (recombinant human insulin), and GLARITUS (recombinant insulin glargine). These commercially available products contribute significantly to their revenue stream and establish a strong market presence.
In addition to its own product development and commercialization, Wockhardt offers contract manufacturing services and provides active pharmaceutical ingredients (APIs) to other companies. This diversification of revenue streams through contract manufacturing enhances the company's overall financial stability and resilience.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other overvalued NSE stocksScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about WOCKHARDT (WOCKPHARMA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of WOCKHARDT (WOCKPHARMA)?
The current share price of WOCKHARDT (WOCKPHARMA) is ₹2,088.70. Today, the stock has gained by ₹138.10 (7.08%), trading in a range of ₹1,976.10 to ₹2,108.50. The stock opened at ₹1,980.00 with a trading volume of 35,57,646 shares.
02Is WOCKHARDT stock a good investment for long-term?
WOCKHARDT can be considered for long-term investment based on several factors. The company has a market capitalization of ₹33,908.05 Cr., P/E ratio of 75.68, ROE of 10.28%, and ROCE of 10.37%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of WOCKHARDT stock?
The 52-week high price of WOCKHARDT (WOCKPHARMA) is ₹2,422.30, while the 52-week low is ₹1,086.70. Currently trading at ₹2,088.70, the stock is 92.21% above its 52-week low and 13.77% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy WOCKHARDT stock at the current price?
Whether to buy WOCKHARDT stock at ₹2,088.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 75.68 and P/B ratio of 6.27. Today's performance shows a gain of 7.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of WOCKHARDT and when is the next dividend?
WOCKHARDT offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹2,088.70, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of WOCKHARDT?
WOCKHARDT's key financial metrics include: P/E Ratio: 75.68, P/B Ratio: 6.27, ROE: 10.28%, ROCE: 10.37%, Dividend Yield: 0%, EPS: ₹6.58, Book Value: ₹325.00, and Debt-to-Equity: 0.57. The company's market cap stands at ₹33,908.05 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is WOCKHARDT stock performing today in the market?
WOCKHARDT stock opened at ₹1,980.00 and is currently trading at ₹2,088.70, showing a gain of ₹138.10 (7.08%). The intraday high is ₹2,108.50 and low is ₹1,976.10. The trading volume stands at 35,57,646 shares, indicating strong market participation today.
08What is the P/E ratio of WOCKHARDT and what does it indicate?
WOCKHARDT has a Price-to-Earnings (P/E) ratio of 75.68, which means investors are willing to pay 75.68 for every ₹1 of earnings. With an EPS of ₹6.58, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about WOCKHARDT (WOCKPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.